Vincerx Pharma, Inc. (VINC)

US — Healthcare Sector
Peers: VRPX  SLXNW  PIII  FOXO  DRMA  REVB  ACON  SYRS  SRZN  PPBT 

Automate Your Wheel Strategy on VINC

With Tiblio's Option Bot, you can configure your own wheel strategy including VINC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

About Vincerx Pharma, Inc. (VINC)

  • IPO Date 2020-05-27
  • Website https://vincerx.com
  • Industry Biotechnology
  • CEO Raquel E. Izumi
  • Employees 12
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. Its lead product candidate is VIP152, a cyclin-dependent kinase-9 inhibitor for treating patients with advanced cancer. The company's preclinical stage product candidates include VIP217, an oral PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate to treat solid tumors; and VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is headquartered in Palo Alto, California.